TruFin has successfully launched on Injective, bringing the institutional-grade liquid staking solution, TruStake, and its liquid staked token, TruINJ, to Injective. This integration brings a new tool and asset for users in the Injective ecosystem that meets strict institutional standards. TruFin is a major institutional player working with giants like Laser Digital to bring about unique yield opportunities for liquid digital asset holdings. TruFin aims to leverage Injective's purpose-built infrastructure due to Injective’s focus on decentralized finance (DeFi), cross-chain compatibility, rapid transaction speeds, and hosting a decentralized network.

What is TruFin?

TruFin provides institutional-grade Web3 primitives, such as liquid staking, that can be used as the foundational building blocks for digital asset strategies. They aim to provide a compliant-first approach to generate rewards from staking revenue, all done transparently on-chain. TruFin has built the core underlying infrastructure & a connected ecosystem to enable multi-chain liquid staking, boasting an impressive ~$270M in total value locked (TVL), as of this posting, from institutional and accredited investors alike. TruFin has made this possible with the support of key integrations with Hex Trust, Twinstake, and Zellic.

Injective's DeFi-focused environment complements TruStake's institutional-grade staking solution, enabling the delivery of more value to users. By joining Injective, TruFin strengthens its ability to provide regulatory-compliant access to liquid staking, reinforced by stringent AML and KYC procedures.

Enhanced Efficiency of TruStake

TruStake on Injective will further enhance usability for users, supported by automatic re-staking of rewards. This automated process maximizes capital efficiency for staked assets without the need for constant manual oversight to re-invest or unstake/restake.

The TruStake solution allows users to stake their INJ while retaining liquidity to put to use across the DeFi ecosystem like liquidity pools, borrow and lending markets, and other yield strategies. Another benefit to TruINJ is the instant redemption via DEX liquidity, allowing a holder of TruINJ to swap immediately to INJ. This is in contrast to the native unstaking process, with an unbounding period of 21 days.

Shared Vision for the Future of DeFi

The launch of TruStake on Injective represents another step in bringing institutional DeFi to the masses. By integrating Injective's unique DeFi features, TruFin is positioned to deliver an efficient, secure, and compliant staking experience that maximizes yield, liquidity, and user experience.

As TruFin goes live on Injective, institutional clients can expect a next-level DeFi experience tailored for growth, compliance, and innovation. This launch is more than a new staking solution—it's a strategic alignment to bring the worlds of DeFi and TradFi closer together.

About Injective

Injective is a lightning fast interoperable layer one blockchain optimized for building the premier Web3 finance applications. Injective provides developers with powerful plug-and-play modules for creating unmatched dApps. INJ is the native asset that powers Injective and its rapidly growing ecosystem. Injective is incubated by Binance and is backed by prominent investors such as Jump Crypto, Pantera and Mark Cuban.

About TruFin

The TruFin Protocol builds institutional-grade Web3 primitives, such as liquid staking, that can be used as the foundational building blocks for digital asset strategies to reduce risk, generate rewards, securely on-chain.

The TruFin Protocol does not provide services to retail customers nor is it intended that any information on TruStake is a promotion, offer, invitation or solicitation for the purchase or sale of any investment and must not be relied upon for the purposes of any investment decision.

Website | dApp | Blog | X | LinkedIn

Disclaimer: This article is for informational purposes only and is not financial or investment advice, or an endorsement of any project. As always, users should do their own research. The information contained in this article is intended to be current at the time of publication, but may not remain so indefinitely.